Drugs / Lirilumab
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03532451 | Mar 2019 → Nov 2020 | urinary bladder cancer | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 1 | NCT03203876 | Jul 2017 → Aug 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02252263 | Dec 2014 → Oct 2017 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01750580 | Dec 2012 → Apr 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03347123 | Mar 2018 → Jan 2021 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01714739 | Oct 2012 → Dec 2019 | cancer, familial, with in vitro Radioresistance | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03341936 | Mar 2018 → Jul 2021 overdue | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02599649 | Mar 2016 → Jan 2019 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02481297 | Jun 2015 → Aug 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02399917 | Apr 2015 → Jul 2018 | acute biphenotypic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01687387 | Oct 2012 → Nov 2016 | acute myeloid leukemia | Innate Pharma | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lirilumab | “evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission” NCT01687387 ↗ |
| Known as | Anti-KIR Antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109500 ↗ |
| Known as | BMS-986015 | “evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission” NCT01687387 ↗ |
| Known as | BMS-986015-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109500 ↗ |
| Known as | IPH2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687387 ↗ |
| Action | Inhibit | “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109500 ↗3“Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109500 ↗ “Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109500 ↗ “Anti-KIR” NCT01714739 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as lirilumab, may interfere with the ability of cancer cells to grow and spread.” NCT02399917 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT01592370 ↗ |
| Target | KIR2DL1 | “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109500 ↗ |
| Target | KIR2DL2 | “Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109500 ↗ |
| Target | KIR2DL3 | “Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109500 ↗ |